Hester Biosciences Intrinsic Value
HESTERBIO • Healthcare
Current Stock Price
₹1423.70
Primary Intrinsic Value
₹1482.80
Market Cap
₹1281 Cr
-48.2%
Downside
Median Value
₹737.78
Value Range
₹431 - ₹1483
Assessment
Trading Above Calculated Value
Safety Margin
-93.0%
HESTERBIO Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1482.80 | ₹1186.24 - ₹1779.36 | +4.2% | EPS: ₹67.40, Sector P/E: 22x |
| Book Value Method | asset | ₹726.67 | ₹654.00 - ₹799.34 | -49.0% | Book Value/Share: ₹363.33, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹737.78 | ₹664.00 - ₹811.56 | -48.2% | Revenue/Share: ₹368.89, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1066.67 | ₹960.00 - ₹1173.34 | -25.1% | EBITDA: ₹96.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹617.21 | ₹493.77 - ₹740.65 | -56.6% | CF Growth: 2.9%, Discount: 15% |
| PEG Ratio Method | growth | ₹431.36 | ₹388.22 - ₹474.50 | -69.7% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1041.33 | ₹937.20 - ₹1145.46 | -26.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹871.11 | ₹784.00 - ₹958.22 | -38.8% | ROE: 17.1%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹726.67 | ₹654.00 - ₹799.34 | -49.0% | EPS: ₹67.40, BVPS: ₹363.33 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
HESTERBIO Intrinsic Value Analysis
What is the intrinsic value of HESTERBIO?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Hester Biosciences (HESTERBIO) is ₹737.78 (median value). With the current market price of ₹1423.70, this represents a -48.2% variance from our estimated fair value.
The valuation range spans from ₹431.36 to ₹1482.80, indicating ₹431.36 - ₹1482.80.
Is HESTERBIO undervalued or overvalued?
Based on our multi-method analysis, Hester Biosciences (HESTERBIO) appears to be trading above calculated value by approximately 48.2%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.97 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 17.1% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 17.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.51x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Hester Biosciences
Additional stock information and data for HESTERBIO
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹65 Cr | ₹55 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹48 Cr | ₹37 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹24 Cr | ₹-15 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹9 Cr | ₹-50 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹58 Cr | ₹37 Cr | Positive Free Cash Flow | 8/10 |